Six-packed antibodies punch better.
作者信息
Rader Christoph, Wiestner Adrian
机构信息
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
出版信息
Haematologica. 2019 Sep;104(9):1696-1699. doi: 10.3324/haematol.2019.224196.
Abstract
摘要
相似文献
1
Six-packed antibodies punch better.六联抗体效果更佳。
Haematologica. 2019 Sep;104(9):1696-1699. doi: 10.3324/haematol.2019.224196.
2
Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".关于“Ⅰ型CD20抗体募集B细胞受体以实现对恶性B细胞的补体依赖性裂解”的评论
J Immunol. 2018 Apr 15;200(8):2515-2516. doi: 10.4049/jimmunol.1800087.
3
Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".
J Immunol. 2018 Apr 15;200(8):2517. doi: 10.4049/jimmunol.1800233.
4
Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.补体调节蛋白CFHR1和CFHR3与患者对抗CD20单克隆抗体治疗的反应
Clin Cancer Res. 2017 Feb 15;23(4):954-961. doi: 10.1158/1078-0432.CCR-16-1275. Epub 2016 Aug 15.
5
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.利妥昔单抗输注可促进慢性淋巴细胞白血病患者快速补体耗竭及急性CD20丢失。
J Immunol. 2004 Mar 1;172(5):3280-8. doi: 10.4049/jimmunol.172.5.3280.
6
T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.携带抗CD3×抗CD20双特异性抗体的T细胞在体外增强了对CD20+恶性B细胞的杀伤作用，并绕过了补体介导的利妥昔单抗耐药性。
Exp Hematol. 2005 Apr;33(4):452-9. doi: 10.1016/j.exphem.2005.01.007.
7
New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.新型 CD20 抗体对 I 型和 II 型 CD20 抗体作用机制的新见解。
Br J Haematol. 2018 Mar;180(6):808-820. doi: 10.1111/bjh.15132. Epub 2018 Feb 22.
8
Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.p53 突变型和 ATM 突变型慢性淋巴细胞白血病细胞对奥法木单抗和利妥昔单抗的体外敏感性不同。
Exp Hematol. 2014 Oct;42(10):867-74.e1. doi: 10.1016/j.exphem.2014.06.003. Epub 2014 Jun 23.
9
Fresh frozen plasma as a complement source.
Lancet Oncol. 2007 May;8(5):370-1. doi: 10.1016/S1470-2045(07)70114-6.
10
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.利妥昔单抗的一种IgG3转换变体对低CD20表达水平的肿瘤细胞介导增强的补体依赖性细胞毒性。
Br J Haematol. 2013 Apr;161(2):282-6. doi: 10.1111/bjh.12209. Epub 2013 Jan 7.
引用本文的文献
1
Antigen-antibody complex density and antibody-induced HLA protein unfolding influence Fc-mediated antibody effector function.抗原-抗体复合物密度和抗体诱导的HLA蛋白解折叠影响Fc介导的抗体效应功能。
Front Immunol. 2024 Dec 18;15:1438285. doi: 10.3389/fimmu.2024.1438285. eCollection 2024.
2
Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy.用于癌症治疗的凋亡诱导肿瘤坏死因子超家族配体
Cancers (Basel). 2021 Mar 27;13(7):1543. doi: 10.3390/cancers13071543.
3
Bispecific antibodies in cancer immunotherapy.双特异性抗体在癌症免疫治疗中的应用。
Curr Opin Biotechnol. 2020 Oct;65:9-16. doi: 10.1016/j.copbio.2019.11.020. Epub 2019 Dec 13.
本文引用的文献
1
Bispecific antibodies: a mechanistic review of the pipeline.双特异性抗体：管线的机制综述。
Nat Rev Drug Discov. 2019 Aug;18(8):585-608. doi: 10.1038/s41573-019-0028-1.
2
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.抗CD37抗体BI 836826用于复发/难治性慢性淋巴细胞白血病的1期首次人体试验。
Leukemia. 2019 Oct;33(10):2531-2535. doi: 10.1038/s41375-019-0475-z. Epub 2019 May 14.
3
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.CD20 和 CD37 抗体通过 Fc 介导的聚集协同激活补体。
Haematologica. 2019 Sep;104(9):1841-1852. doi: 10.3324/haematol.2018.207266. Epub 2019 Feb 21.
4
The Many and Varied Roles of Tetraspanins in Immune Cell Recruitment and Migration.四跨膜蛋白在免疫细胞募集和迁移中的多种不同作用
Front Immunol. 2018 Jul 18;9:1644. doi: 10.3389/fimmu.2018.01644. eCollection 2018.
5
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.针对CD37的研究性疗法用于治疗B细胞淋巴瘤。
Expert Opin Investig Drugs. 2018 Feb;27(2):171-177. doi: 10.1080/13543784.2018.1427730. Epub 2018 Jan 15.
6
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.利妥昔单抗治疗B细胞血液系统恶性肿瘤：20年临床经验回顾
Adv Ther. 2017 Oct;34(10):2232-2273. doi: 10.1007/s12325-017-0612-x. Epub 2017 Oct 5.
7
Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life.治疗性Fc工程进展——IgG相关效应功能及血清半衰期的调控
Front Immunol. 2016 Dec 12;7:580. doi: 10.3389/fimmu.2016.00580. eCollection 2016.
8
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.奥妥珠单抗与苯达莫司汀联合用药对比苯达莫司汀治疗复发慢性淋巴细胞白血病的随机2期研究
Br J Haematol. 2017 Feb;176(4):618-628. doi: 10.1111/bjh.14464. Epub 2016 Dec 15.
9
Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.抗原结合后能有效形成六聚体的抗体在补体限制条件下可诱导补体依赖的细胞毒性。
J Immunol. 2016 Sep 1;197(5):1762-75. doi: 10.4049/jimmunol.1600648. Epub 2016 Jul 29.
10
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.一种基于细胞表面IgG六聚体的抗原依赖性形成来增强治疗性抗体的新型平台。
PLoS Biol. 2016 Jan 6;14(1):e1002344. doi: 10.1371/journal.pbio.1002344. eCollection 2016 Jan.
Zotero 插件